South Korean Aesthetics Firms Expand in US to Target GLP-1 Volume Loss

South Korean medical aesthetics companies are accelerating their expansion into the United States medspa industry to capture the growing demand for treatments addressing facial volume loss caused by GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. Reported on August 9, 2026, this strategic push includes major moves by prominent manufacturers. PharmaResearch, the company behind the Rejuran polynucleotide skin booster, has secured a partnership with the major US medspa chain LaserAway. This brings their regenerative skin treatment directly to a massive footprint of American patients looking to restore skin quality. Meanwhile, South Korean aesthetics firm Hugel has appointed industry veteran Carrie Strom as its global CEO to spearhead its expansion in the United States. For independent practice owners, this influx of well-backed South Korean brands means more competitive options to address the rapid facial volume loss associated with weight-loss therapies. You should expect to see these brands heavily marketing to your patient demographic, making it a good time to evaluate how polynucleotides like Rejuran fit into your current clinical offerings.

Source: KED Global, https://www.kedglobal.com/aesthetics/newsView/ked202608090001